Samsung BioLogics Co Ltd

Company Profile

• Business description

  Founded in 2011, Samsung Biologics, or Samsung Bio, is the largest contract development, research, and manufacturing organization, or CDRMO, globally in terms of manufacturing capacity. The company has 785,000 kiloliters of capacity as of 2025, with plans to acquire another 60,000 kL plant in Maryland in 2026. Samsung Bio entered the research business in June 2025, making it a full-service company offering clients preclinical, front-to-end service. It spun off Samsung Bioepis in October 2025 after its acquisition in 2022, which develops biosimilars for its own pipeline. The spinoff was meant to make Samsung Bio a pure play CDMO business. Samsung C&T and Samsung Electronics own about 43% and 31% of Samsung Bio, respectively. The company competes with Wuxi Biologics, Lonza, and Fujifilm.

• Contact

  300, Songdo Bio-Daero
  Yeonsu-Gu
  Incheon21987
  KOR

  T: +82 324553114

  https://www.samsungbiologics.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2026

  Employees

  5,273